| Health / Medical Topics |
Gomiliximab
IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This chimeric monoclonal antibody binds to the CD23 receptor, by which IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways. (NCI Thesaurus)
YOU MAY ALSO LIKE
An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with…
An orally bioavailable synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and…
A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent…
Human GOLM1 wild-type allele is located in the vicinity of 9q21.33 and is approximately 74 kb in length. This allele, which encodes…
This gene is involved in both the trafficking and posttranslational modification of proteins.
A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. Golimumab binds to TNF-a, thereby preventing…
